Klassen Preston 4
4 · Regulus Therapeutics Inc. · Filed Jan 10, 2025
Insider Transaction Report
Form 4
Klassen Preston
DirectorPresident & Head of R & D
Transactions
- Award
Common Stock
2025-01-09$1.36/sh+37,500$51,000→ 37,500 total - Award
Common Stock
2025-01-09$1.30/sh+30,000$39,000→ 67,500 total
Footnotes (2)
- [F1]On August 10, 2023, the reporting person was granted Restricted Stock Units (RSUs). The RSUs only vest upon achievement of a specified performance-based milestone. The performance criteria were met resulting in immediate vesting of 50% of the shares subject to the grant. The remaining 50% vest on the one year anniversary of the vesting commencement date, subject to the reporting person's Continuous Service to Regulus.
- [F2]On January 12, 2024, the reporting person was granted Restricted Stock Units (RSUs). The RSUs only vest upon achievement of a specified performance-based milestone. The performance criteria were met resulting in immediate vesting of 50% of the shares subject to the grant. The remaining 50% vest on the one year anniversary of the vesting commencement date, subject to the reporting person's Continuous Service to Regulus.